Dosing & Uses
Dosage Forms & Strengths
- 20mg/mL (100mg/vial)
- 20mg/mL (200mg/vial)
- 20mg/mL (400mg/vial)
Indicated for wild-type KRAS (exon 2 in codons 12 or 13) metastatic colororectal carcinoma (mCRC) as determined by an FDA-approved test for this use (eg, therascreen KRAS RGQ PCR Kit)
Indications for monotherapy and combination
- Combination, first-line therapy: Indicated in combination with FOLFOX, as first-line treatment in patients with wild-type KRAS (exon 2) mCRC
- Monotherapy following disease progression: Indicated as monotherapy for the treatment of EGFR-expressing mCRC in patients with disease progression after prior treatment with fluoropyrimidine-, oxaliplatin-, and irinotecan-containing chemotherapy
Limitation of use
- Not indicated for the treatment of patients with RAS-mutant mCRC or for whom RAS mutation status is unknown
- Prior to treatment initiation, assess RAS mutational status in colorectal tumors and confirm the absence of a RAS mutation
Infusion Reactions: Mild-moderate (grade 1-2) reduce rate by 50%; Severe (grade 3-4) permanently discontinue
- First occurrence of grade 3 dermatologic reaction: Withhold 1 to 2 doses; if reaction improves to <grade 3, reinitiate at the original dose
- Second occurrence of grade 3 dermatologic reaction: Withhold 1 to 2 doses; if reaction improves to <grade 3, reinitiate at 80% of the original dose
- Third occurrence of grade 3 dermatologic reaction: Withhold 1 to 2 doses; if reaction improves to <grade 3, reinitiate at 60% of the original dose
- Fourth occurrence of grade 3 dermatologic reaction: Permanently discontinue
- Grade 3 or 4 dermatologic reaction that does not recover to <grade 3: Permanently discontinue
Safety and efficacy not established
Acneiform dermatitis (57%)
Abdominal pain (25%)
Skin exfoliation (25%)
Skin fissures (20%)
Dermatologic toxicity, Grade 3 and 4 (14% )
Peripheral edema (12%)
Abdominal pain, Grade 3 and 4 (7% )
Pulmonary embolism, Grades 3 to 5 (7% )
Hypomagnesemia, Grade 3 and 4 (4% )
Angioedema, All grades (3% to 4% )
Complication of infusion, All grades (3% to 4% )
Constipation, Grade 3 and 4 (3% )
Binding antibodies (0.4-3.8%)
Diarrhea, Grade 3 and 4 (2% )
Vomiting, Grade 3 and 4 (2% )
Nausea, Grade 3 and 4 (1% )
Anaphylaxis (1% )
Complication of infusion, Grade 3 and 4 (1% )
Frequency Not Defined
Growth of eyelashes
Skin and subcutaneous tissue disorders: Skin necrosis, angioedema
Immune system disorders: Anaphylactoid reaction
Eye disorders: Keratitis/ulcerative keratitis
Life threatening and fatal bullous mucocutaneous disease
Black Box Warnings
- Dermatologic toxicities, some severe (NCI-CTC grade 3 or higher), related to panitumumab blockade of EGF binding and subsequent inhibition of EGFR-mediated signaling pathways have been reported in patients receiving panitumumab monotherapy
- Dermatologic toxicities were reported in 90% of patients and were severe in 15% of patients receiving monotherapy
- Clinical manifestations included, but were not limited to, dermatitis acneiform, pruritus, erythema, rash, skin exfoliation, paronychia, dry skin, and skin fissures
- Severe dermatologic toxicities were complicated by infection including sepsis, septic death, and abscesses requiring incisions and drainage
- It could not be determined whether these mucocutaneous adverse reactions were directly related to EGFR inhibition or to idiosyncratic immune-related effects (eg, Stevens Johnson syndrome or toxic epidermal necrolysis)
- Withhold or discontinue panitumumab and monitor for inflammatory or infectious sequelae in patients with severe dermatologic toxicities
Increased tumor progression, increased mortality, or lack of benefit in patients with RAS-mutant mCRC; determine RAS-mutant tumor status in an experienced laboratory using an FDA-approved test before treatment
Monitor patients who develop dermatologic toxicities while receiving panitumumab for the development of inflammatory or infectious sequelae; limit sun exposure
Panitumumab is not indicated for use in combination with chemotherapy due to increase in mortality or toxicity
Permanently discontinue in patients developing pulmonary fibrosis/interstitial lung disease
Monitor for keratitis or ulcerative keratitis; interrupt or discontinue panitumumab for acute or worsening keratitis
Monitor electrolytes and institute appropriate treatment if needed
Terminate the infusion for severe infusion reactions
Ocular toxicities reported; monitor for keratitis or ulcerative keratitis; interrupt or discontinue for acute or worsening keratitis
Discontinue permanently if patient develops interstitial lung disease, pneumonitis, or lung infiltrates
Pregnancy & Lactation
Pregnancy Category: C
Lactation: not known if excreted in breast milk, do not nurse during & for at least 2 mth post-treatment
A:Generally acceptable. Controlled studies in pregnant women show no evidence of fetal risk.
B:May be acceptable. Either animal studies show no risk but human studies not available or animal studies showed minor risks and human studies done and showed no risk.
C:Use with caution if benefits outweigh risks. Animal studies show risk and human studies not available or neither animal nor human studies done.
D:Use in LIFE-THREATENING emergencies when no safer drug available. Positive evidence of human fetal risk.
X:Do not use in pregnancy. Risks involved outweigh potential benefits. Safer alternatives exist.
NA:Information not available.
Mechanism of Action
Human monoclonal antibody to human EGF receptor
Peak Plasma Concentration: 213±59 mcg/mL
Trough Concentration: 39±14 mcg/mL
Half-Life, Elimination: 7.5 days
Clearance: 4.9±1.4 mL/kg/day
Colorectal cancer expressing with KRAS wild-type respond more favorably to regimens that include anti-EGFR antibodies (cetuximab, panitumumab); whereas, the presence of KRAS mutation (codon 12 or 13) showed an absence of biological and clinical activity for the anti-EGFR antibody treatment
Strongly recommended that patients with metastatic CRC who are being considered for treatment with anti-EGFR antibody therapy should be tested for the presence of a KRAS mutation prior to the administration of therapy (NCCN guidelines)
Genetic testing laboratories
- The following companies are currently offering KRAS mutation status testing
- Clarient, Inc. (http://www.clarientinc.com)
- Caris Diagnostics (http://www.carisdx.com)
- DxS (http://www.dxsdiagnostics.com)
- Genzyme Genetics (http://www.genzymegenetics.com)
- LabCorp (http://www.labcorp.com)
- Response Genetics (http://www.responsegenetics.com)
Inspect vial; discard if discolored
Some particulate matter may be present, OK to use (will be removed by filter)
Withdraw dose amount & dilute to 100 mL with 0.9% NaCl (if dose >1 g, in 150 mL)
Mix by gentle inversion, do not shake
Final concentration not to exceed 10 mg/mL
Use diluted solution within 6 hr if stored at room temp, or within 24 hr if stored at 2-8°C
Use low-protein-binding 0.2-0.22 micron in-line filter
Flush IV line with 0.9% NaCl before and after administration
Use infusion pump
Infuse over 60 min ( 90 min if dose >1 g) through peripheral line or indwelling catheter
Adding plans allows you to compare formulary status to other drugs in the same class.
To view formulary information first create a list of plans. Your list will be saved and can be edited at any time.
Adding plans allows you to:
- View the formulary and any restrictions for each plan.
- Manage and view all your plans together – even plans in different states.
- Compare formulary status to other drugs in the same class.
- Access your plan list on any device – mobile or desktop.
The above information is provided for general informational and educational purposes only. Individual plans may vary and formulary information changes. Contact the applicable plan provider for the most current information.
|1||This drug is available at the lowest co-pay. Most commonly, these are generic drugs.|
|2||This drug is available at a middle level co-pay. Most commonly, these are "preferred" (on formulary) brand drugs.|
|3||This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs.|
|4||This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.|
|5||This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.|
|6||This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.|
|NC||NOT COVERED – Drugs that are not covered by the plan.|
Drugs that require prior authorization. This restriction requires that specific clinical criteria be met prior to the approval of the prescription.
Drugs that have quantity limits associated with each prescription. This restriction typically limits the quantity of the drug that will be covered.
Drugs that have step therapy associated with each prescription. This restriction typically requires that certain criteria be met prior to approval for the prescription.
Drugs that have restrictions other than prior authorization, quantity limits, and step therapy associated with each prescription.